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Abstract
Background: Although caffeine supplementation improves performance, the ergogenic effect is variable. The
cause(s) of this variability are unknown. A (C/A) single nucleotide polymorphism at intron 1 of the cytochrome
P450 (CYP1A2) gene influences caffeine metabolism and clinical outcomes from caffeine ingestion. The purpose of
this study was to determine if this polymorphism influences the ergogenic effect of caffeine supplementation.
Methods: Thirty-five trained male cyclists (age = 25.0 ± 7.3 yrs, height = 178.2 ± 8.8 cm, weight = 74.3 ± 8.8 kg,
VO2max = 59.35 ± 9.72 ml·kg
-1·min
-1) participated in two computer-simulated 40-kilometer time trials on a cycle
ergometer. Each test was performed one hour following ingestion of 6 mg·kg
-1 of anhydrous caffeine or a placebo
administered in double-blind fashion. DNA was obtained from whole blood samples and genotyped using
restriction fragment length polymorphism-polymerase chain reaction. Participants were classified as AA
homozygotes (N = 16) or C allele carriers (N = 19). The effects of treatment (caffeine, placebo) and the treatment ×
genotype interaction were assessed using Repeated Measures Analysis of Variance.
Results: Caffeine supplementation reduced 40 kilometer time by a greater (p < 0.05) magnitude in AA
homozygotes (4.9%; caffeine = 72.4 ± 4.2 min, placebo = 76.1 ± 5.8 min) as compared to C allele carriers (1.8%;
caffeine = 70.9 ± 4.3 min, placebo = 72.2 ± 4.2 min).
Conclusions: Results suggest that individuals homozygous for the A allele of this polymorphism may have a larger
ergogenic effect following caffeine ingestion.
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Background
Prior studies have established the ergogenic benefits of
caffeine for both high-intensity short-duration perfor-
mances [1-3], as well as endurance performance [4-6].
However, based on two studies that have reported indi-
vidual data [3,6], approximately 30% of participants
derive no ergogenic effects from caffeine ingestion. Doh-
erty et al. [3] observed that four out of 14 subjects had
no appreciable change in time to fatigue during running
at a supramaximal workload following ingesting of caf-
feine. Meyers and Cafarelli [6] investigated the effects of
acute caffeine supplementation on time to fatigue during
repetitive quadriceps contractions. Three out of the 10
study participants did not respond to the caffeine or
exhibited a worse performance under caffeine versus the
placebo. Furthermore, not all studies report a significant
ergogenic effect [7-9]. Beck et al. [7] did not observe
any effect of caffeine on either maximal bench press
strength or time to fatigue at 85% VO2max. Jacobson et
al. [8] observed that caffeine had no additive effect on
time trial performance when administered with pre-
exercise carbohydrate or fat feedings. Finally, caffeine
had no effect on peak power output or total work in a
short-duration maximal cycling test [9]. Thus, the ergo-
genic effect of caffeine, while evident, is highly variable.
The cause(s) of this variability across individuals
remains unclear, and it is unknown if any of this var-
iance is accounted for by genetic polymorphisms.
Cytochrome P450 is a hepatic enzyme that is a key
component of caffeine metabolism. A (C/A) single
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P450 gene influences the inducibility of this enzyme,
with the C variant affecting a slower caffeine metabo-
lism following caffeine ingestion in smokers [10]. This
polymorphism has clinical importance, as caffeine
increases risk for cardiovascular disease in individuals
who possess the C variant, but not in individuals homo-
zygous for the A variant [11,12], presumably due to a
slower caffeine clearance in the former group. In con-
trast, Hallstrom et al. [13] observed that coffee con-
sumption contributes to low bone mineral density in
individuals homozygous for the A variant, and not those
who possess the C allele. Therefore, this genetic poly-
morphism is a potential candidate to explain variability
of ergogenic response to caffeine supplementation. The
purpose of the present study was to determine if this
specific CYP1A2 polymorphism influences the ergogenic
effect of caffeine supplementation in trained cyclists.
Methods
Subjects
A total of 36 male recreationally competitive cyclists
participated in the present study. One of these partici-
pants was excluded from the study post-hoc, as their
cycling performance differed by more than two standard
deviations from the mean value of the group. Therefore,
35 cyclists (age = 25.0 ± 7.3 yrs, height = 178.2 ± 8.8
cm, weight = 74.3 ± 8.8 kg, VO2max = 59.35 ± 9.72
ml·kg
-1·min
-1) were used for data analysis. Written
informed consent was obtained from all participants
prior to participation and the study and consent form
were approved by the James Madison University Institu-
tional Review Board. Habitual caffeine intake was self-
reported by participants. Briefly, participants were asked
for their average weekly intake of coffee, tea, soda, cho-
colate, and other caffeinated beverages. Typical milli-
gram doses [14] were assigned to each and an
approximate daily intake was obtained. Based on pre-
vious criteria [15], participants were then characterized
as having low (0-150 mg·day
-1), moderate (151-300
mg·day
-1) and high (> 300 mg·day
-1) caffeine intake.
Maximal exercise test
Cyclists began the test at a work rate of 150 W on an
electrically braked cycle ergometer, with load increases
of 20 W each minute until volitional exhaustion. Maxi-
mal oxygen uptake (VO2max) was defined as the highest
1-minute oxygen value obtained during the test. Oxygen
uptake (VO2) was monitored continuously via a Sensor-
medics Vmax (Yorba Linda, CA) metabolic measure-
ment system calibrated in advance of all tests. Heart
rate was monitored throughout the test using a Polar
Heart Rate Monitor (Lake Success, NY).
40-kilometer time trial
Time trials were performed on two separate occasions.
All testing was done in the morning following a 12-hour
fast and at least 24 hours after any caffeine ingestion.
Subjects were instructed to maintain their training and
not increase or decrease their volume or intensity over
the course of the study. One hour prior to testing,
cyclists ingested capsules containing either 6 mg of
anhydrous caffeine per kilogram body weight or white
flour (placebo) randomly administered in double-blind
fashion. Time trials were performed on an indoor cycle
trainer (Velotron; Racermate, Seattle, WA) on a compu-
ter-simulated course. The course consisted of eight laps
of a flat, five-kilometer loop. Cyclists were free to self-
s e l e c tt h er e s i s t a n c eb yc h a n g i n gg e a r sd u r i n gt h et e s t
and were allowed to track distance completed on the
course via a video display. However, they were blinded
to their time, speed, and power output during the trials.
Water was available for the cyclists to ingest ad libitum.
Oxygen uptake and respiratory exchange ratio (RER)
were obtained and averaged over the last two minutes
of each lap. Heart rate and Ratings of Perceived Exertion
(RPE; using the original 6-20 Borg scale) were obtained
at the end of each lap.
Genotyping
Investigators were blinded to genotype until the subject
completed the study. Furthermore, all genotyping was
performed by an investigator not involved with the per-
formance testing. DNA was obtained from whole blood
samples via a QiaAmp mini-blood kit (Qiagen Inc.;
Valencia, CA). Each blood sample was obtained prior to
one of the cycling trials. Genotyping was performed
using restriction fragment length polymorphism-poly-
merase chain reaction (RFLP-PCR), as previously
d e s c r i b e d[ 1 2 ] .B r i e f l y ,D NA was PCR amplified using
the HotStar DNA Polymerase Kit (Qiagen) with the for-
ward primer (5’-CAACCCTGCCAATCTCAAGCAC-3’)
and reverse primer (5’-AGAAGCTCTGTGGCCGA-
GAAGG-3’) to generate a 920 bp fragment of the
CYP1A2 gene. PCR conditions consisted of an initial
denaturation at 95°C for 5 minutes, followed by 39
cycles at 94°C for 15 seconds, 64.5°C for 1 minute, and
72°C for 1 minute, with a final elongation step of 72°C
for 10 minutes. One half of each PCR product was
digested using the restriction enzyme ApaI (New Eng-
land Biolabs, Ipswich, MA) as per manufacturer’s
instructions. Digested and undigested PCR products
were evaluated in parallel via electrophoresis in a 2%
agarose gel stained with ethidium bromide, and DNA
bands were visualized by UV light. The presence of a
920 bp fragment following ApaI digestion identified the
A/A genotype, while the presence of 709 bp and 211 bp
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genotype. Caffeine metabolism is similar between het-
erozygotes and CC homozygotes [10]. Therefore, similar
to previous studies [11,12], cyclists were grouped as AA
homozygotes and C allele carriers; the latter group
including both heterozygotes and CC homozygotes.
Statistical analyses
Descriptive data (height, weight, age, VO2max, caffeine
intake) were compared between groups using indepen-
dent t-tests. The frequency of low, moderate and high
caffeine intake in the two genetic groups was compared
using a Chi-Squared analysis. Potential differences in
40-km time, average VO2, HR, RER and RPE were
assessed using repeated measures analysis of variance
(RMANOVA) with treatment as a within-subjects factor
and genotype as a between-subjects factor. For all RMA-
NOVA procedures, post-hoc tests were performed using
independent and dependent t-tests with a Bonferroni
correction such that P < 0.025 was required for
significance.
Results
Out of the 35 participants analyzed, 16 (46%) were
homozygous for the A variant and 19 (54%) were C
allele carriers. This distribution is very similar to pre-
viously reported studies [10-12,15]. Descriptive charac-
teristics of the two genotype groups are shown in Table
1. There were no significant differences (p >0 . 0 5 )
between the two groups for height, weight, age,
VO2max, or caffeine intake. In AA homozygotes, 12 out
of the 16 participants were categorized as having low
caffeine intake, three as moderate and one as high. Six-
teen out of the 19 C allele carriers had low intake, one
had moderate intake, with two characterized as having
high intake. There was no difference in the distribution
of low, moderate and high caffeine use between the two
groups (p = 0.44).
Figure 1 displays the average 40-km times for both
groups. There was a significant (p < 0.001) main effect
for Treatment (Caffeine < Placebo) and a significant (p
= 0.005) Treatment × Genotype interaction, such that
caffeine lowered average (mean ± SD) 40-km time in
AA homozygotes (4.9%; caffeine = 72.4 ± 4.2 min, pla-
cebo = 76.1 ± 5.8 min) to a greater degree than the C
allele carriers (1.8%; caffeine = 70.9 ± 4.3 min, placebo =
72.2 ± 4.2 min). Caffeine significantly decreased 40-km
time in the AA homozygotes (p <0 . 0 0 1 ) ,w i t has t r o n g
trend towards decreased 40-km time in C allele carriers
(p = 0.04). Individual data for the 40-km times in both
groups are displayed in Figure 2. Note that data points
above the line of identity reflect an improvement in 40-
km time in the caffeine trial. Caffeine resulted in at least
a1 - m i n u t ei m p r o v e m e n ti n4 0kt i m ei n1 5o u to ft h e
16 AA homozygotes; whereas only 10 out of 19 C allele
carriers observed this degree of improvement. Average
RPE, VO2, RER and heart rate for the 40-km time trial
are shown in Table 2. There was a main effect for
Treatment for both VO2 and HR, with both variables
higher in the caffeinated condition versus placebo (p <
0.001). Furthermore, there was a main effect of Geno-
type for VO2, with C allele carriers exhibiting signifi-
cantly higher average VO2 than AA homozygotes (p =
0.03). There were no significant main effects or interac-
tion effects for RPE or RER.
Discussion
The major finding of the present study is that caffeine
affects 40-kilometer time trial performance in cyclists
homozygous for the A variant to a greater degree than
those who possess the C variant. Specifically, caffeine
decreased 40-km time by an average of 3.8 minutes in
the AA homozygotes as compared to 1.3 minutes in the
C allele carriers. To our knowledge, this is the first
study to implicate a specific polymorphism as a poten-
tial cause of the variation in the ergogenic effect of caf-
feine supplementation.
Sachse et al. [10] observed slower caffeine metabolism
in C allele carriers who smoke, suggesting that this
CYP1A2 polymorphism may affect the inducibility of
the Cytochrome P450 enzyme. Caffeine has also been
shown to increase risk of heart disease in C allele car-
riers but not AA homozygotes [11,12], ostensibly
because caffeine is metabolized at a higher rate in the
AA homozygotes. Given these prior findings, it could be
hypothesized that a slower metabolism would be advan-
tageous for maximizing the ergogenic benefit of caffeine.
Alternatively, Hallstrom et al. [13] found that coffee
consumption was associated with decreased bone
mineral density in AA homozygotes, but not C allele
carriers. The authors speculated that the rapid accumu-
lation of caffeine metabolites may have been responsible
for this finding [13]. In support of this contention, para-
xanthine and theophylline (downstream metabolites of
caffeine metabolism) have higher binding affinities with
adenosine receptors than caffeine [16]. Thus, it is
Table 1 Descriptive data for AA homozygotes and C
allele carriers
A/A (n = 16) C (n = 19)
Height (cm) 179.1 ± 10.6 178.0 ± 7.1
Weight (kg) 74.3 ± 12.5 73.7 ± 12.2
Age 24.0 ± 6.9 26.1 ± 7.8
VO2max (L·min
-1) 4.30 ± 0.45 4.31 ± 0.58
VO2max (ml·kg
-1·min
-1) 59.04 ± 9.29 59.61 ± 10.31
Caffeine intake (mg per day) 85.71 ± 106.49 86.62 ± 145.40
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zygotes created a more rapid production of paraxanthine
and/or theophylline and therefore enhanced the ergo-
genic effect. This possibility is speculative as no markers
of caffeine metabolism were available. Future studies
should determine caffeine metabolism during exercise
across these genotypes to better determine the mechan-
ism of the observed effect.
Despite the fact that there was a significant Genotype
× Treatment interaction for 40-km time, it should also
be noted that the AA homozygotes had a slower placebo
40-km time and the caffeine supplementation served to
Figure 1 Average (mean ± SE) 40 kilometer time for the caffeine and placebo treatments for both groups. *-Significantly (p < 0.05)
larger decrease in 40 K time than the C allele carriers.
Figure 2 40-km time in both the placebo condition (y-axis) and the caffeinated condition (x-axis) for both AA homozygotes and C
allele carriers. The line of identity is plotted and reflects no difference between the two trials. Data points above the line of identity reflect an
improved 40-km time in the caffeinated condition.
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comparable to C allele carriers (Figure 1). This raises
the concern that the results were driven by a difference
in cycling performance capabilities between the two
groups, rather than the genetic polymorphism. Collomp
et al. [17] observed that caffeine improved swimming
velocity in trained, but not untrained swimmers.
O’Rourke et al. [18] observed a similar 5-km perfor-
mance improvement from caffeine in both well-trained
and recreational runners. Thus, one would expect per-
formance capabilities to have no effect on caffeine
response, or to affect it in the opposite direction of
what was observed in the present study. Nonetheless,
we further addressed the difference in performance
between the two groups in a follow-up analysis. Because
the higher 40-km time in AA homozygotes was primar-
ily driven by four cyclists whose 40 k times during the
placebo trial were greater than 80 minutes (see Figure
2), we removed these four subjects from the dataset for
the follow-up analysis. Thisr e s u l t e di ns i m i l a r4 0 - k m
times in the placebo condition between the two groups,
yet caffeine still had a significantly (p = 0.047) greater
effect in AA homozygotes (caffeine = 70.5 ± 3.0 min,
placebo = 73.5 ± 3.8 min) compared to the C allele car-
riers (caffeine = 70.9 ± 4.3 min, placebo = 72.2 ± 4.2
min). Caffeine resulted in at least a 1-minute improve-
ment in 40 k time in all but one of the AA homozy-
gotes; whereas only about half of C allele carriers
responded to that extent (Figure 2). Thus, our data sup-
port the contention that it is the genetic polymorphism
and not the performance capabilities of the respective
groups that explain our observations.
Although data from the present study clearly suggest a
potential role of this polymorphism in influencing the
ergogenic response of caffeine in cyclists, care should be
taken in extrapolating these findings. It is unknown if
there is a similar genetic influence for other modes of
exercise and/or for short-duration high-intensity exer-
cise. Furthermore, we used trained cyclists in the pre-
sent study and our findings cannot be extrapolated to
sedentary individuals. Neither can it be suggested that
this polymorphism is the only source of variation or
even the only source of genetic variation involved.
Finally, although we have outlined a potential mechan-
ism that explains the current findings, it should be
emphasized that the mechanistic causes of our findings
cannot be determined from the present data. Future stu-
dies should determine whether these findings can be
replicated using other modes of exercise and in other
populations. Other candidate polymorphisms should
also be identified and evaluated.
Conclusions
In summary, data from the present study suggest that
caffeine potentiates a larger ergogenic effect for cycling
performance in individuals homozygous for the A var-
iant of the studied CYP1A2 polymorphism. The
mechanism(s) of this selective ergogenic effect are
unknown and future studies should seek to establish the
impact of this polymorphism on caffeine metabolism
during exercise. While these findings elucidate a possi-
ble source of variance in the ergogenic effect of caffeine,
other factors, including other genetic polymorphisms,
may also influence caffeine responses during exercise.
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Table 2 Average (mean ± SD) values during the 40 k trial
for Ratings of Perceived Exertion, VO2, Respiratory
Exchange Ratio, and Heart Rate
RPE Genotype Caffeine Placebo
AA 14.3 ± 1.6 14.2 ± 1.6
C 15.0 ± 1.4 14.9 ± 1.4
VO2 (L·min
-1)
ab
AA 3.08 ± 0.41 2.88 ± 0.49
C 3.43 ± 0.48 3.23 ± 0.48
RER
AA 0.92 ± 0.05 0.91 ± 0.04
C 0.94 ± 0.05 0.94 ± 0.04
HR (beats per min)
a
AA 162 ± 10 153 ± 11
C 170 ± 13 163 ± 14
a-Main effect for Treatment (p < 0.05)
b-Main effect for Genotype (p < 0.05)
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